NXPI
NXP SEMICONDUCTORS N.V.
(NASDAQ:NXPI)
Balfour Capital Group Researched NXP Semiconductors N.V. (NXPI) on April 13th, 2023.
NXP Semiconductors N.V. is a Dutch semiconductor manufacturer headquartered in Eindhoven, Netherlands. The company designs purpose-built, rigorously tested technologies that enable devices to sense, think, connect, and act intelligently, aiming to improve people’s daily lives. Their solutions address complex challenges in automotive, industrial, mobile, and communication infrastructure sectors.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $170.22 on April 13th, 2023.
- Our designated price target stands at $230.69
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy NXP SEMICONDUCTORS N.V. (NXPI) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
HON
HONEYWELL INTERNATIONAL INC
(NASDAQ:HON)
Balfour Capital Group Researched Honeywell International Inc on April 13th, 2023.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $193.23 on April 13th, 2023.
- Our designated price target stands at $225.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy HONEYWELL INTERNATIONAL INC (HON) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ADM
ARCHER DANIELS MIDLAND CO.
(NYSE:ADM)
Balfour Capital Group has issued a buy recommendation
for Archer Daniels Midland Co. (ADM) on May 10th, 2023.
Archer-Daniels-Midland Company (ADM) is an American multinational corporation specializing in food processing and commodities trading. Founded in 1902 and headquartered in Chicago, Illinois, ADM operates over 270 plants and 420 crop procurement facilities worldwide. The company processes cereal grains and oilseeds into products used in various markets, including food, beverage, nutraceutical, industrial, and animal feed.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $53.07 on May 10th, 2023.
- Our designated price target stands at $95.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Archer Daniels Midland Co. (ADM) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
DOW
DOW INC.
(NYSE:DOW)
Balfour Capital Group has issued a buy recommendation
for Dow Inc. (DOW) on June 5th, 2023.
The Dow Chemical Company, headquartered in Midland, Michigan, is a multinational corporation and subsidiary of Dow Inc. Operating in around 160 countries with 36,000 employees, it primarily sells to other industries. Dow merged with DuPont in 2017, forming DowDuPont, and later separated in 2019.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $51.69 on June 5th, 2023.
- Our designated price target stands at $75.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Dow Inc. (DOW) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
HCA
HCA HEALTHCARE INC
(NYSE:HCA)
Balfour Capital Group Researched HCA Healthcare Inc on June 7th, 2023.
HCA Healthcare, Inc. is one of the nation’s leading providers of healthcare services. As of the latest data, the company owns and operates 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics across 20 states and the United Kingdom. HCA is committed to delivering healthcare services that meet the diverse needs of the communities it serves.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $271.19 on June 7th, 2023.
- Our designated price target stands at $435.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy HCA HEALTHCARE INC (HCA) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
AMZN
AMAZON.COM INC.
(NASDAQ:AMZN)
Balfour Capital Group has issued a buy recommendation for Amazon.com Inc. (AMZN) on June 7th, 2023.
Amazon, founded by Jeff Bezos on July 5, 1994, in Bellevue, Washington, started as an online bookstore and expanded into “The Everything Store.” It owns subsidiaries like Amazon Web Services, Zoox, Kuiper Systems, Ring, Twitch, IMDb, and Whole Foods Market. Amazon also offers streaming services and produces consumer electronics.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $127.01 on June 7th, 2023.
- Our designated price target stands at $244.34
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Amazon.com Inc. (AMZN) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BKR
BAKER HUGHES CO.
(NASDAQ:BKR)
Balfour Capital Group has issued a buy recommendation
for Baker Hughes Co (BKR) on June 8th, 2023.
Baker Hughes Company, based in Houston, Texas, is a leading oil field services company operating in over 120 countries. It offers products and services for drilling, formation evaluation, completion, production, and reservoir consulting. Formerly majority-owned by GE, Baker Hughes is now independent.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $30.71 on June 8th, 2023.
- Our designated price target stands at $47.78
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Baker Hughes Co (BKR) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
QCOM
QUALCOMM INC.
(NASDAQ: QCOM)
Balfour Capital Group has issued a buy recommendation
for Qualcomm Inc. (QCOM) on June 9th, 2023
Qualcomm Incorporated, headquartered in San Diego and incorporated in Delaware, creates semiconductors, software, and services for wireless technology. Founded in 1985, it owns key patents for 5G, 4G, CDMA2000, TD-SCDMA, and WCDMA standards. Qualcomm’s products include components for vehicles, watches, laptops, Wi-Fi, and smartphones.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $117.49 on June 9th, 2023.
- Our designated price target stands at $205.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Qualcomm Inc. (NASDAQ:QCOM) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
V
VISA INC.
(NYSE:V)
Balfour Capital Group has issued a buy recommendation
for Visa Inc. (V) on June 14th, 2023.
Visa Inc. is an American multinational payment card services corporation headquartered in San Francisco, California. It facilitates global electronic funds transfers through Visa-branded credit, debit, and prepaid cards. Founded in 1958 as BankAmericard, it became Visa in 1976, providing financial institutions with Visa-branded payment products. VisaNet processes nearly all transactions through four secure data centers worldwide.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $223.74 on June 14th, 2023.
- Our designated price target stands at $335.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Visa Inc. (V) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BMY
BRISTOL MYERS SQUIBB CO
(NYSE:BMY)
Balfour Capital Group has issued a buy recommendation for Bristol Myers Squibb Co (BMY) on July 24th, 2023.
BBristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company focuses on areas such as oncology, immunology, cardiovascular diseases, and fibrosis.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $64.70 on July 24th, 2023.
- Our designated price target stands at $75.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Bristol Myers Squibb Co (NYSE:BMY) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*